Having demonstrated that ruxolitinib effectively reduces tumorigenesis when administered at early stages of tumor formation, we questioned whether ruxolitinib prevents progression of already established K‐RAS‐driven lung AC in a therapeutic setting. This evidence concerns the gene KRAS and neoplasm.